替罗非班对急性ST段抬高型心肌梗死并糖尿病患者急诊经皮冠状动脉介入治疗术后血清MMP-9水平的影响及临床意义

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (7): 807-811.

替罗非班对急性ST段抬高型心肌梗死并糖尿病患者急诊经皮冠状动脉介入治疗术后血清MMP-9水平的影响及临床意义

邓少雄¹, 郭南鸥², 郑渊¹, 黄文森¹

¹福建省泉州医学高等专科学校内科教研室,泉州 362000, 福建;
²福建医科大学附属泉州市第一医院心内科, 泉州 362000,福建

收稿日期:2011-05-16 修回日期:2011-06-28 出版日期:2011-07-26 发布日期:2011-09-22
作者简介:邓少雄,男,本科,副教授,主要从事心血管内科的临床研究。Tel: 0896-5521763 E-mail: drdengsx@126.com
基金资助:
泉州市科技局基金资助项目(2007Z51)

Effect and clinical significance of tirofiban on serum matrix metalloproteinase 9 after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction and diabetes

DENG Shao-xiong¹, GUO Nan-ou², ZHENG-Yuan¹, HUANG Wen-sen¹

¹Medical Department of Quanzhou Medical College, Quanzhou 362000, Fujian,China;
²Department of Heart Internal Medicine, Affiliated the First Hospital of Quanzhou,Fujian Medical University, Quanzhou 362000, Fujian,China

Received:2011-05-16 Revised:2011-06-28 Online:2011-07-26 Published:2011-09-22

摘要/Abstract

摘要： 目的: 探讨替罗非班对急性ST段抬高型心肌梗死(STEMI)并糖尿病患者急诊经皮冠状动脉介入治疗(PCI)术后血清基质金属蛋白酶-9(MMP-9)水平的影响及临床意义。方法: 急诊PCI治疗的STEMI并糖尿病患者123例,分为常规治疗组61例和替罗非班组62例。分别比较两组患者一般临床资料及冠状动脉病变情况,比较两组患者急诊PCI术前及术后的血清MMP-9水平,比较两组患者在PCI术后12个月冠状动脉支架内再狭窄的发生率。结果: 两组患者一般临床资料、冠状动脉病变狭窄程度和病变血管数目差异均无统计学意义(P>0.05);两组患者PCI术后血清MMP-9水平较术前明显增高,差异有统计学意义(P<0.05);替罗非班组在PCI术后MMP-9水平与常规治疗组比较明显降低,差异有统计学意义(P<0.05);在PCI术后替罗非班组支架内再狭窄发生率低,与常规治疗组比较差异有统计学意义(P<0.05)。结论: STEMI并糖尿病患者急诊PCI术后血清MMP-9水平增高,替罗非班能通过降低MMP-9的表达来降低患者支架植入术后再狭窄的发生率。

关键词: 替罗非班, 心肌梗死, 糖尿病, 经皮冠状动脉介入治疗, 基质金属蛋白酶-9

Abstract: AIM: To study the effect and clinical significance of tirofiban on serum matrix metalloproteinase 9(MMP-9) and after primary percutaneous coronary intervention(PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI)and diabetes.METHODS: One hundred and twenty-three patients with acute STEMI and diabetes who were treated with primary PCI were designed into two groups: routine treatment group(61 cases) and tirofiban group(62cases).The clinical datas and coronary arterydisorders datas in two groups were compared.The serum MMP-9 levels among two groups before and after primary PCI were detected, as well as the incidences of in-stent restenosis(ISR) at 12 months after primary PCI.RESULTS: The clinical datas,the degreee of coronary stenosis and the number of lesion vessels were similar between the two groups(P>0.05). The levels of MMP-9 in the two groups were both significantly higher after PCI(P<0.05).The level of MMP-9 after PCI from the tirofiban group was obviously lower than that in the routine treatment group(P<0.05).The incidence of in-stent restenosis(ISR) from the tirofiban group was distinctly lower than that in the routine treatment group(P<0.05).CONCLUSION: The level of serum MMP-9 is higher after the primary PCI in patients with acute STEMI and diabetes.The tirofiban can reduce the incidence of post-stenting restenosis by the means of degrading the level of MMP-9.

Key words: Tirofiban, Myocardial infarction, Diabetes, Primary percutaneous coronary intervention, Matrix metalloproteinase-9

中图分类号:

R542.22

邓少雄, 郭南鸥, 郑渊, 黄文森. 替罗非班对急性ST段抬高型心肌梗死并糖尿病患者急诊经皮冠状动脉介入治疗术后血清MMP-9水平的影响及临床意义[J]. 中国临床药理学与治疗学, 2011, 16(7): 807-811.

DENG Shao-xiong, GUO Nan-ou, ZHENG-Yuan, HUANG Wen-sen. Effect and clinical significance of tirofiban on serum matrix metalloproteinase 9 after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction and diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 807-811.

参考文献

[1] Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation metalloproteinase-9 and pmenosis of patients with cardiovascular disease[J]. Circulation, 2006,107(12):1579-1585.
[2] Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil mediated release and activation of matrix metalloprotein ase 9 in myocardial ischemia/ reperfusion[J]. Circulation, 2007,103 (17):2181-2187.
[3] Kaden JJ, Dempfle CE, Sueselbeck T,et al. Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction[J]. Cardiology, 2003,99(3):140-144.
[4] Tao ZY, Cavasin MA, Yang F, et al. Temporal changes in matrix metal loproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice[J]. Life Sci,2004, 74(12):1561-1572.
[5] Moses JW, Moussa I, Leon MB, et al. Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanaly-sis of the GAMMA I randomized trial)[J].Am J Cardiol,2005,90(3):243-247.
[6] Nishioka T. The incidence and mechanism of restenosis after PTCA [J].Nippon Rinsho,2007,61(Suppl4):511-517.
[7] Knobler H,Savion N,Shenkman B, et al.Shear-induced-platelet adhesion and aggregation on subendothelium are increased in diabetic patients[J].Thromb Res,2002,90(4):181-190.
[8] Mason DP, Kenagy RD, Hasenstab D, et al.Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery[J]. Circ Res,1999,85(12):1179-1185.
[9] May AE,Kalsch T,Massberg S, et al. Engagement of glycoprotein Ⅱb/Ⅲa on platelets up regulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells[J]. Circulation,2002,106(16):2111-2117.
[10] Uyarel H,Uzunlar B,Unal Dayi S,et al.Effect of tirufiban therapyon ST segement resolution and clinical outcomes in patients wit STsegement elevated acute myocardial infarction undergoing primaryangioplasty[J].Cardiology,2006,105(3):169-175.

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[3]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[4]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[5]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[6]	钱锦, 王峰岩. 老年急性心肌梗死患者PCI术后血清NT-proBNP水平的影响因素并分析其对近期预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(6): 658-665.
[7]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[8]	张雪娇, 刘洁婷, 李鲁新, 陈培剑, 丁明璐, 孙梦伟, 初彦辉, 张珍. 达格列净对1型糖尿病小鼠心肌损伤的影响及机制研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 257-265.
[9]	白佳, 杨虹, 李玲玲, 张洋洋, 杨莹, 吕海宏. 维生素D通过线粒体/自噬途径影响糖尿病神经病变机制的研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 214-219.
[10]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[11]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[12]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[13]	杨丽, 柏虎虎, 贺沙沙, 金月, 刘成松. TRPM3的酪氨酸磷酸化参与糖尿病诱发的热痛觉过敏[J]. 中国临床药理学与治疗学, 2022, 27(9): 971-976.
[14]	庞胜峰, 张晶, 吴宁宁, 李茹, 曹军, 何胜虎. 急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J]. 中国临床药理学与治疗学, 2022, 27(9): 1004-1009.
[15]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.